TrialAntimicrobial agents and chemotherapy2019

Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota.

Barbara K Lomeli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.